nu crypto currency- Top Knowledge graph

Haitong Securities: The moderate price reduction of traditional Chinese medicine varieties continues. The domestic pharmaceutical industry is expected to set off a wave of mergers and acquisitions. Haitong Securities released a research report saying that the moderate price reduction of traditional Chinese medicine varieties continues. In 2024, the traditional Chinese medicine industry was under pressure due to the pressure of pharmacy terminal sales and inventory pressure, and it is expected to return to a good situation in the next 25 years. In addition, the continuous technological changes in the pharmaceutical industry, the development of IPO to mergers and acquisitions and the promotion of corporate governance optimization at the shareholder level are the main reasons for promoting mergers and acquisitions in the industry. In terms of fields, mergers and acquisitions are expected to occur intensively in sub-sectors such as medical devices, Chinese medicine, medical services, blood products and scientific research services.According to people familiar with the matter, Trump's advisers and officials from his newly formed government efficiency department asked him if he could abolish the Federal Deposit Insurance Corporation (FDIC).A delegation of Japanese young and middle-aged military officers visited China. Today, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, said that at the invitation of China Institute of International Strategic Studies, a delegation of Japanese young and middle-aged military officers will visit China from November 26th to December 4th. The Sino-Japanese exchange program for young and middle-aged officers began in 2001, which played an important role in enhancing understanding and trust between the defense departments of the two countries. We are willing to work with Japan to continue to promote mutual visits and exchanges and provide positive energy for the improvement and development of bilateral relations.

Yingsi Intelligent announced that it had received a milestone payment of $10 million from Exelixis. On December 13th, Yingsi Intelligent, a biomedical technology company, announced that based on the progress made in the clinical stage of XL309(ISM3091) project, the company had recently received the first clinical milestone payment from Exelixis, with a total amount of $10 million.Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.The American medical insurance giant said that the suspect who assassinated its CEO was not a company customer. A spokesman for UnitedHealth Group said that Luigi Mangione, the suspect accused of killing Brian Thompson, CEO of the company's United Health Care, was not a member of the company's insurance plan. Unitedhealth group said that Man Ghione and his mother were not members of United Health Insurance Company, and refuted the claim that the shooting incident was caused by dissatisfaction caused by his special experience in the company.

Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.A delegation of Japanese young and middle-aged military officers visited China. Today, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, said that at the invitation of China Institute of International Strategic Studies, a delegation of Japanese young and middle-aged military officers will visit China from November 26th to December 4th. The Sino-Japanese exchange program for young and middle-aged officers began in 2001, which played an important role in enhancing understanding and trust between the defense departments of the two countries. We are willing to work with Japan to continue to promote mutual visits and exchanges and provide positive energy for the improvement and development of bilateral relations.Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.